Nirogacestat

Last Updated: 04/28/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 63 publications

How have gamma-secretase inhibitors changed the treatment landscape for desmoid tumors?

How have gamma-secretase inhibitors changed the treatment landscape for desmoid tumors?

Journal: Expert opinion on pharmacotherapy

Published: February 18, 2026

The role of γ-secretase in familial hidradenitis suppurativa: Implications for pathogenesis and targeted therapy.

The role of γ-secretase in familial hidradenitis suppurativa: Implications for pathogenesis and targeted therapy.

Journal: JAAD case reports

Published: January 15, 2026

Androgenic hidradenitis suppurativa onset linked to gamma secretase inhibitor.

Androgenic hidradenitis suppurativa onset linked to gamma secretase inhibitor.

Journal: JAAD case reports

Published: January 09, 2026

Are we managing desmoid tumors correctly in Spain? Results of the first national survey.

Are we managing desmoid tumors correctly in Spain? Results of the first national survey.

Journal: Cirugia espanola

Published: December 16, 2025

AQbD-driven development of a green RP-HPLC method for nirogacestat with LC-MS structural elucidation.

AQbD-driven development of a green RP-HPLC method for nirogacestat with LC-MS structural elucidation.

Journal: BMC chemistry

Published: November 07, 2025

Efficacy and Safety of Long-Term Continuous Nirogacestat Treatment in Adults With Desmoid Tumors: Results From the DeFi Trial.

Efficacy and Safety of Long-Term Continuous Nirogacestat Treatment in Adults With Desmoid Tumors: Results From the DeFi Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: October 20, 2025

Regulatory Signaling Pathways in Ovarian Cancer Stem Cells: Their Role in Tumor Progression and Therapeutic Strategies.

Regulatory Signaling Pathways in Ovarian Cancer Stem Cells: Their Role in Tumor Progression and Therapeutic Strategies.

Journal: Iranian biomedical journal

Published: September 29, 2025

Case Report: Nirogacestat therapy induces rapid response in a patient with refractory, life-threatening desmoid tumor.

Case Report: Nirogacestat therapy induces rapid response in a patient with refractory, life-threatening desmoid tumor.

Journal: Frontiers in oncology

Published: September 27, 2025

Disproportionality analysis of dermatologic adverse events associated with nirogacestat: Insights from the U.S. Food and Drug Administration Adverse Event Reporting System.

Disproportionality analysis of dermatologic adverse events associated with nirogacestat: Insights from the U.S. Food and Drug Administration Adverse Event Reporting System.

Journal: Journal of the American Academy of Dermatology

Published: September 05, 2025

Repurposing nirogacestat, a gamma secretase enzyme inhibitor in desmoid tumors.

Repurposing nirogacestat, a gamma secretase enzyme inhibitor in desmoid tumors.

Journal: Future oncology (London, England)

Published: September 01, 2025

Rapid biocompatible solid phase microextraction: Nirogacestat protein binding in post dose human serum samples.

Rapid biocompatible solid phase microextraction: Nirogacestat protein binding in post dose human serum samples.

Journal: Journal of chromatography. B, Analytical technologies in the biomedical and life sciences

Published: August 29, 2025

New onset hidradenitis suppurativa and eruptive milia associated with gamma secretase inhibitor therapy in a patient with desmoid tumor: A case report.

New onset hidradenitis suppurativa and eruptive milia associated with gamma secretase inhibitor therapy in a patient with desmoid tumor: A case report.

Journal: JAAD case reports

Published: August 11, 2025

Showing 1-12 of 63

Last Updated: 04/28/2026